Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation : the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT / L. Garderet, S. Iacobelli, P. Moreau, F. Onida, C. Koenecke, T. Pabst, C. Doyen, C. Crawley, R. Hajek, W. Linkesch, J.L. Harousseau, M. Michallet, Z. Doran, T. De Witte, D. Niederwieser, G. Gahrton, C. Morris on behalf of the Chronic Leukemia Working Party of the EBMT. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - 43:Supplement 1(2009 Apr), pp. S30-S30. ((Intervento presentato al 35. convegno Annual Meeting of the European Group for Blood and Marrow Transplantation tenutosi a Göteborg, Sweden nel 2009.

Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) versus Thalidomide-Dexamethasone to treat multiple myeloma (MM) patients progressing or relapsing after autologous transplantation : the MMVAR trial, a study from the myeloma subcommittee of the Chronic Leukemia Working Party of the EBMT

F. Onida;
2009

Settore MED/15 - Malattie del Sangue
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/57612
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact